Fig. 2From: A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells top: Hydrolysis of TMZ to generate the inactive AIC and the methyl diazonium species; bottom: Hydrolysis of EG22 to regenerate ANI, the naked PARP inhibitor, and the same methyl diazonium species as temozolomideBack to article page